PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
The phosphoinositide 3-kinase (PI3-kinase) signaling pathway is frequently aberrantly activated in glioblastoma multiforme (GM) by mutation or loss of the 3' phospholipid phosphatase PTEN. PTEN abnormalities result in inappropriate signaling to downstream molecules including protein kinase B (PKB/Akt), and mammalian target of rapamycin (mTOR). PI3-kinase activation increases resistance to radiation-induced cell death; conversely, PI3-kinase inhibition enhances the sensitivity of tumors to radiation. The effects of LY294002, a biochemical inhibitor of PI3-kinase, on the response to radiation were examined in the PTEN mutant glioma cell line U251 MG. Low doses of LY294002 sensitized U251 MG to clinically relevant doses of radiation. In contrast to LY294002, rapamycin, an inhibitor of mTOR, did not result in radiosensitization. We demonstrate that among multiple known targets of LY294002, PI3-kinase is the most likely molecule responsible for LY294002-induced radiosensitization. Furthermore, using a myristoylated PKB/Akt construct, we identified PKB/Akt as the downstream molecule that mediates the synergistic cytotoxicity between LY294002 and radiation. Thus PI3-kinase dysregulation may contribute to the notable radioresistance of GM tumors and inhibition of PKB/Akt offers an excellent target to enhance radiosensitivity.
Nakamura
Jean L
JL
Department of Radiation Oncology, The University of California, San Francisco, CA 94143, USA.
Karlsson
Amelia
A
Arvold
Nils D
ND
Gottschalk
Alexander R
AR
Pieper
Russell O
RO
Stokoe
David
D
Haas-Kogan
Daphne A
DA
D000077329:Agammaglobulinaemia Tyrosine Kinase; D000704:Analysis of Variance; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001932:Brain Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000532:radiotherapy; D045744:Cell Line, Tumor; D002867:Chromones / Q000494:pharmacology*; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D005909:Glioblastoma / Q000201:enzymology* / Q000235:genetics / Q000532:radiotherapy; D006801:Humans; D009025:Morpholines / Q000494:pharmacology*; D009154:Mutation; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases / Q000187:drug effects; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010744:Phosphoric Monoester Hydrolases / Q000187:drug effects* / Q000235:genetics; D011494:Protein Kinases / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000187:drug effects*; D011518:Proto-Oncogene Proteins / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*; D020123:Sirolimus / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D025521:Tumor Suppressor Proteins / Q000187:drug effects* / Q000235:genetics
D000077329:Agammaglobulinaemia Tyrosine Kinase; D000903:Antibiotics, Antineoplastic; D002867:Chromones; D004791:Enzyme Inhibitors; D009025:Morpholines; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010744:Phosphoric Monoester Hydrolases; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D011838:Radiation-Sensitizing Agents; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; D025521:Tumor Suppressor Proteins; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C546842:MTOR protein, human; C494918:AKT1 protein, human; C494929:PTEN protein, human
Curr Biol. 1998 Oct 22;8(21):1195-8
9799739
Proc Natl Acad Sci U S A. 2001 Aug 28;98 (18):10314-9
11504908
Mol Cell. 2001 Mar;7(3):559-70
11463381
Cancer Res. 2001 Mar 1;61(5):2105-11
11280773
Cell Cycle. 2003 Jul-Aug;2(4):339-45
12851486
Radiat Res. 1987 Nov;112(2):331-40
3685260
Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):846-53
12788194
J Biol Chem. 2002 Feb 15;277(7):5484-9
11729185
Mol Cell Biol. 2003 Sep;23 (17 ):6139-49
12917336
Oncogene. 1999 Jul 8;18(27):3936-43
10435616
Clin Cancer Res. 1997 Jul;3(7):1149-56
9815794
Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1699-707
4030437
Oncogene. 2002 Jun 6;21(25):4032-41
12037685
Cancer Res. 2001 May 15;61(10 ):4278-82
11358856
Cancer Chemother Pharmacol. 1993;32(6):477-81
8258197
J Biol Chem. 1998 Jan 2;273(1):200-6
9417065
Clin Cancer Res. 2001 Mar;7(3):682-90
11297265
Cancer Res. 1998 Jul 15;58(14):2973-7
9679957
J Neurosurg. 1999 Nov;91(5):822-30
10541240
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):421-5
11173136
Proc Natl Acad Sci U S A. 2001 Aug 28;98 (18):10320-5
11504907
Brain Pathol. 1999 Jul;9(3):469-79
10416987
J Biol Chem. 1997 Dec 12;272(50):31515-24
9395488
Cell Signal. 2002 May;14(5):381-95
11882383
J Biol Chem. 1998 May 8;273(19):11937-43
9565622
Cancer Res. 2002 Dec 15;62(24):7291-7
12499272